Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 3
1982 3
1984 8
1985 3
1986 11
1987 8
1988 7
1989 11
1990 17
1991 23
1992 27
1993 38
1994 28
1995 36
1996 23
1997 32
1998 17
1999 21
2000 45
2001 27
2002 28
2003 30
2004 10
2005 28
2006 26
2007 37
2008 31
2009 25
2010 20
2011 24
2012 31
2013 31
2014 26
2015 26
2016 21
2017 15
2018 11
2019 12
2020 17
2021 33
2022 32
2023 16
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

863 results

Results by year

Filters applied: . Clear all
Page 1
A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness.
Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, Rahman M, Zaman K, Somani J, Yasmin R, Hasnat MA, Kabir A, Aziz AB, Khan WA. Ahmed S, et al. Int J Infect Dis. 2021 Feb;103:214-216. doi: 10.1016/j.ijid.2020.11.191. Epub 2020 Dec 2. Int J Infect Dis. 2021. PMID: 33278625 Free PMC article. Clinical Trial.
A randomized, double-blind, placebo-controlled trial was conducted to determine the rapidity of viral clearance and safety of ivermectin among adult SARS-CoV-2 patients. The trial included 72 hospitalized patients in Dhaka, Bangladesh, who were assigned to one of three gro …
A randomized, double-blind, placebo-controlled trial was conducted to determine the rapidity of viral clearance and safety of ivermectin …
Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Gentile N, Collins S, McCarthy MW, Jayaweera D, Castro M, Sulkowski M, McTigue K, Thicklin F, Felker GM, Ginde AA, Bramante CT, Slandzicki AJ, Gabriel A, Shah NS, Lenert LA, Dunsmore SE, Adam SJ, DeLong A, Hanna G, Remaly A, Wilder R, Wilson S, Shenkman E, Hernandez AF; Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-6) Study Group and Investigators. Naggie S, et al. JAMA. 2022 Oct 25;328(16):1595-1603. doi: 10.1001/jama.2022.18590. JAMA. 2022. PMID: 36269852 Free PMC article. Clinical Trial.
The median time to recovery was 12 days (IQR, 11-13) in the ivermectin group and 13 days (IQR, 12-14) in the placebo group. There were 10 hospitalizations or deaths in the ivermectin group and 9 in the placebo group (1.2% vs 1.2%; HR, 1.1 [95% CrI, 0.4-2.6]). The mo …
The median time to recovery was 12 days (IQR, 11-13) in the ivermectin group and 13 days (IQR, 12-14) in the placebo group. There wer …
Effect of Early Treatment with Ivermectin among Patients with Covid-19.
Reis G, Silva EASM, Silva DCM, Thabane L, Milagres AC, Ferreira TS, Dos Santos CVQ, Campos VHS, Nogueira AMR, de Almeida APFG, Callegari ED, Neto ADF, Savassi LCM, Simplicio MIC, Ribeiro LB, Oliveira R, Harari O, Forrest JI, Ruton H, Sprague S, McKay P, Guo CM, Rowland-Yeo K, Guyatt GH, Boulware DR, Rayner CR, Mills EJ; TOGETHER Investigators. Reis G, et al. N Engl J Med. 2022 May 5;386(18):1721-1731. doi: 10.1056/NEJMoa2115869. Epub 2022 Mar 30. N Engl J Med. 2022. PMID: 35353979 Free PMC article. Clinical Trial.
RESULTS: A total of 3515 patients were randomly assigned to receive ivermectin (679 patients), placebo (679), or another intervention (2157). ...There were no significant effects of ivermectin use on secondary outcomes or adverse events. CONCLUSIONS: Treatment with …
RESULTS: A total of 3515 patients were randomly assigned to receive ivermectin (679 patients), placebo (679), or another intervention …
Comparison of topical benzyl benzoate vs. oral ivermectin in treating scabies: A randomized study.
Meyersburg D, Welponer T, Kaiser A, Selhofer S, Tatarski R, Handisurya A, Bauer JW. Meyersburg D, et al. J Eur Acad Dermatol Venereol. 2023 Jan;37(1):160-165. doi: 10.1111/jdv.18573. Epub 2022 Sep 23. J Eur Acad Dermatol Venereol. 2023. PMID: 36097258 Free PMC article. Clinical Trial.
After initial therapy failure in group A, six out of eight patients showed treatment response upon repeated application of BB, five of five when retreated with ivermectin and two of two with BB plus ivermectin, respectively. In group B, successful retreatment was ob …
After initial therapy failure in group A, six out of eight patients showed treatment response upon repeated application of BB, five of five …
The efficacy of permethrin 5% vs. oral ivermectin for the treatment of scabies.
Ranjkesh MR, Naghili B, Goldust M, Rezaee E. Ranjkesh MR, et al. Ann Parasitol. 2013;59(4):189-94. Ann Parasitol. 2013. PMID: 24791346 Free article. Clinical Trial.
The aim of this study is to compare the efficacy and safety of permethrin 5% lotion with oral ivermectin for the treatment of scabies. In total, 60 patients with scabies were enrolled, and randomized into two groups: The first group and their family contacts received 5% pe …
The aim of this study is to compare the efficacy and safety of permethrin 5% lotion with oral ivermectin for the treatment of scabies …
Ivermectin compared with placebo in the clinical course in Mexican patients with asymptomatic and mild COVID-19: a randomized clinical trial.
de la Rocha C, Cid-López MA, Venegas-López BI, Gómez-Méndez SC, Sánchez-Ortiz A, Pérez-Ríos AM, Llamas-Velázquez RA, Meza-Acuña AI, Vargas-Íñiguez B, Rosales-Galván D, Tavares-Váldez A, Luna-Gudiño N, Hernández-Puente CV, Milenkovic J, Iglesias-Palomares C, Méndez-Del Villar M, Gutiérrez-Dieck GA, Valderrábano-Roldán CG, Mercado-Cerda J, Robles-Bojórquez JG, Mercado-Sesma AR. de la Rocha C, et al. BMC Infect Dis. 2022 Dec 8;22(1):917. doi: 10.1186/s12879-022-07890-6. BMC Infect Dis. 2022. PMID: 36482326 Free PMC article. Clinical Trial.
However, the evidence is not strong or weak enough to conclude its usefulness in the clinical evolution of patients infected with SARS-CoV-2. We evaluate the efficacy and safety of ivermectin in the treatment of Mexican patients with asymptomatic and mild COVID-19 in a thr …
However, the evidence is not strong or weak enough to conclude its usefulness in the clinical evolution of patients infected with SARS-CoV-2 …
Efficacy, safety, and tolerability of albendazole and ivermectin based regimens for the treatment of microfilaraemic loiasis in adult patients in Gabon: A randomized controlled assessor blinded clinical trial.
Zoleko-Manego R, Kreuzmair R, Veletzky L, Ndzebe-Ndoumba W, Ekoka Mbassi D, Okwu DG, Dimessa-Mbadinga-Weyat LB, Houtsa-Temgoua RD, Mischlinger J, McCall MBB, Kresmner PG, Agnandji ST, Lell B, Adegnika AA, Mombo-Ngoma G, Ramharter M. Zoleko-Manego R, et al. PLoS Negl Trop Dis. 2023 Aug 28;17(8):e0011584. doi: 10.1371/journal.pntd.0011584. eCollection 2023 Aug. PLoS Negl Trop Dis. 2023. PMID: 37639396 Free PMC article. Clinical Trial.
BACKGROUND: There is a lack of systematic evidence for strategies to control loiasis transmission in highly endemic regions. Here we assessed albendazole and ivermectin based treatment regimens to reduce Loa loa microfilaraemia in Gabon. ...CONCLUSION: The 5-week regimen o …
BACKGROUND: There is a lack of systematic evidence for strategies to control loiasis transmission in highly endemic regions. Here we assesse …
Efficacy and safety of ivermectin for the treatment of Plasmodium falciparum infections in asymptomatic male and female Gabonese adults - a pilot randomized, double-blind, placebo-controlled single-centre phase Ib/IIa clinical trial.
Ekoka Mbassi D, Mombo-Ngoma G, Held J, Okwu DG, Ndzebe-Ndoumba W, Kalkman LC, Ekoka Mbassi FA, Pessanha de Carvalho L, Inoue J, Akinosho MA, Dimessa Mbadinga LB, Yovo EK, Mordmüller B, Kremsner PG, Adegnika AA, Ramharter M, Zoleko-Manego R. Ekoka Mbassi D, et al. EBioMedicine. 2023 Nov;97:104814. doi: 10.1016/j.ebiom.2023.104814. Epub 2023 Oct 13. EBioMedicine. 2023. PMID: 37839134 Free PMC article. Clinical Trial.
BACKGROUND: Ivermectin's mosquitocidal effect and in vitro activity against Plasmodium falciparum asexual stages are known. Its in vivo blood-schizonticidal efficacy is unknown. Ivermectin's tolerability and efficacy against P. falciparum infections in …
BACKGROUND: Ivermectin's mosquitocidal effect and in vitro activity against Plasmodium falciparum asexual stages are known. It …
Ivermectin role in COVID-19 treatment (IRICT): single-center, adaptive, randomized, double-blind, placebo-controlled, clinical trial.
Elshafie AH, Elsawah HK, Hammad M, Sweed EM, Seif AS, Abdel Ghaffar MM, Goda FM, Mosalam EM, Abdallah MS. Elshafie AH, et al. Expert Rev Anti Infect Ther. 2022 Oct;20(10):1341-1350. doi: 10.1080/14787210.2022.2098113. Epub 2022 Jul 12. Expert Rev Anti Infect Ther. 2022. PMID: 35788169 Retracted. Clinical Trial.
BACKGROUND: To investigate the efficacy and safety of ivermectin compared to hydroxychloroquine and placebo in hospitalized moderate to severe COVID-19 patients. ...RESULTS: Ivermectin decreased survival time from 29 to 18.3 days (HR, 9.8, 95%CI, 3.7-26.2), while it …
BACKGROUND: To investigate the efficacy and safety of ivermectin compared to hydroxychloroquine and placebo in hospitalized moderate …
Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial.
Lim SCL, Hor CP, Tay KH, Mat Jelani A, Tan WH, Ker HB, Chow TS, Zaid M, Cheah WK, Lim HH, Khalid KE, Cheng JT, Mohd Unit H, An N, Nasruddin AB, Low LL, Khoo SWR, Loh JH, Zaidan NZ, Ab Wahab S, Song LH, Koh HM, King TL, Lai NM, Chidambaram SK, Peariasamy KM; I-TECH Study Group. Lim SCL, et al. JAMA Intern Med. 2022 Apr 1;182(4):426-435. doi: 10.1001/jamainternmed.2022.0189. JAMA Intern Med. 2022. PMID: 35179551 Free PMC article. Clinical Trial.
IMPORTANCE: Ivermectin, an inexpensive and widely available antiparasitic drug, is prescribed to treat COVID-19. Evidence-based data to recommend either for or against the use of ivermectin are needed. OBJECTIVE: To determine the efficacy of ivermectin in pre …
IMPORTANCE: Ivermectin, an inexpensive and widely available antiparasitic drug, is prescribed to treat COVID-19. Evidence-based data …
863 results